04.12.21 Best Practices For Implementing Decentralized Clinical Trials
Sponsor
Is clinical development prepared for the paradigm shift caused by COVID-19? The pandemic has forced the industry to reevaluate how to engage with patients and acquire patient data without direct, in-person access. Biopharmaceutical companies, medical device companies, and CROs from around the world were surveyed to explore the impact on clinical trials in this new paradigm and gain insights into their experiences operationalizing trials in a pandemic. Learn more.
Featured Editorial
By Sam Brown, Nell Haslett-Brousse, Ryan Quinn, and John Theodore, Point B
While the experience design related to the patient is paramount to the adoption of decentralized clinical trial technology, the interrelated experience and incentives for all stakeholders must be fully aligned to realize the full benefits of these platforms.
02.17.21 Why Did Veeva Become A Public Benefit Corporation?
With the spread of SARS-CoV-2 (COVID-19) intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring life-saving drugs to market. Attend this webinar to learn more about bringing life-saving drugs to market faster without impacting product quality, safety, or efficacy and the impacts and comparisons of classic platforms vs. new-generation platforms. And more!
By Ed Miseta, chief editor, Clinical Leader
On February 1, 2021, Veeva Systems officially became a Public Benefit Corporation (PBC). With this move, it becomes the first technology company supporting life sciences to transition to a PBC and it is also the first publicly traded corporation in any industry to make that move. How will the designation benefit the company?